论文部分内容阅读
美国生物遗传科学公司(ABS)7月17日在京宣布,将其专利无抗原技术(AF)无偿提供给协和医科大学和中国医学科学院实验动物研究所,这将表明用于生产高特异性单克隆抗体的无抗原小鼠群体第一次在美国以外的国家出现。AF 技术在肿瘤学、血液学、免疫缺陷及基础生物医学和临床应用上有着广阔的前景和商业潜能。ABS 公司主席 Alfred J Roach(右二)表示,之所以选择医科院的实验动物研究所作为 AF 小鼠技术的第二基地,是看中了该研究所在转基因小鼠领域
On July 17, the American Biological Genetic Science Company (ABS) announced that it will provide its patented Antigen-Free Technology (AF) to Kyowa Medical University and the Institute of Experimental Animals of Chinese Academy of Medical Sciences at no cost to the public, demonstrating that the technology used to produce high-specificity monoclonal Antibody-free antigen-free mouse populations appear for the first time in countries outside the United States. AF technology has broad prospects and commercial potential in oncology, hematology, immunodeficiency and basic biomedical and clinical applications. ABS chairman Alfred J Roach (second from right) said that the reason for choosing the Institute of Experimental Animals as the second base for AF mouse technology was to take a fancy to the Institute’s field of transgenic mice